12/4
05:00 pm
crvo
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Medium
Report
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
12/2
09:04 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
12/2
07:00 am
crvo
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
Medium
Report
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
11/24
07:00 am
crvo
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Medium
Report
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
11/11
08:09 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
11/10
07:00 am
crvo
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Low
Report
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
11/5
07:19 am
crvo
CervoMed (NASDAQ:CRVO) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
Low
Report
CervoMed (NASDAQ:CRVO) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
11/4
08:42 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
11/4
07:00 am
crvo
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
Low
Report
CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
10/28
08:00 am
crvo
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
Medium
Report
CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
10/20
08:00 am
crvo
CervoMed to Present at the Emerging Growth Conference
Medium
Report
CervoMed to Present at the Emerging Growth Conference
10/17
07:02 am
crvo
CervoMed (NASDAQ:CRVO) was given a new $20.00 price target on by analysts at Roth Capital. They now have a "buy" rating on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) was given a new $20.00 price target on by analysts at Roth Capital. They now have a "buy" rating on the stock.
10/8
07:00 am
crvo
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Medium
Report
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
10/7
08:00 am
crvo
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
Low
Report
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
10/2
08:00 am
crvo
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Low
Report
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
9/17
07:30 am
crvo
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
Medium
Report
CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
9/8
08:05 am
crvo
CervoMed (NASDAQ:CRVO) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
CervoMed (NASDAQ:CRVO) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.